VXLLF (Vaxil Bio) ROCE %: -33.16% (As of Mar. 2026)


VXLLF Vaxil Bio Ltd VXLLF
38 GF Score
Price $0.02
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio ROCE %?

Vaxil Bio VXLLF -85.27% 38 ROCE % is -33.16% as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vaxil Bio's annualized ROCE % for the quarter that ended in Mar. 2026 was -33.16%.

Vaxil Bio  (OTCPK:VXLLF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vaxil Bio ROCE % Related Terms

Vaxil Bio ROCE % Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio ROCE % Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -78.73 -39.74 -25.73 -17.84 -17.44

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.79 -22.64 -18.62 -17.40 -33.16
VXLLF
38GF Score
Vaxil Bio Ltd VXLLF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio ROCE % Calculation

Vaxil Bio's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-0.13/( ( (0.514 - 0.012) + (0.993 - 0.004) )/ 2 )
=-0.13/( (0.502+0.989)/ 2 )
=-0.13/0.7455
=-17.44 %

Vaxil Bio's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-0.316/( ( (0.993 - 0.004) + (0.943 - 0.026) )/ 2 )
=-0.316/( ( 0.989 + 0.917 )/ 2 )
=-0.316/0.953
=-33.16 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -33.16% mean?
Vaxil Bio (VXLLF) has a ROCE % of -33.16% as of Mar. 2026.
Is Vaxil Bio's ROCE % too high?
Vaxil Bio's current ROCE % is -33.16%. Overall, Vaxil Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's ROCE % compare to VRTX and REGN?
Vaxil Bio's ROCE % of -33.16% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vaxil Bio's current ROCE % is -33.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current ROCE % of -33.16%. The current ROCE % is -33.16%. Vaxil Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current ROCE % is -33.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
38GF Score

Get the complete analysis for VXLLF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price